Home > News > Altair Nanotechnologies Testing RenaZorb With 2nd Pharm. Co.
January 27th, 2003
Altair Nanotechnologies Testing RenaZorb With 2nd Pharm. Co.
Abstract:
Altair Nanotechnologies Inc. (Nasdaq:ALTI) announced that it has entered into a testing agreement with a second pharmaceutical company for in vivo (animal) evaluation of RenaZorb(TM), its new pharmaceutical candidate for phosphate control in kidney dialysis patients.
Source:
BusinessWire
Related News Press |
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||